Dyax Corp. (NASDAQ:DYAX) declared constructive topline results from its ordinal Phase 3, placebo-controlled trial, EDEMA4, for its advance creation politician DX-88 (ecallantide) for transmissible angioedema (HAE). The EDEMA4 trial, conducted low a Special Protocol Assessment acknowledged by the U.S. Food and Drug Administration (FDA), achieved statistically momentous improvements in the intent-to-treat accumulation in direct and alternative endpoints.

Tags: Led, Population